Acutus Medical

Acutus Medical, Inc. engages in the development of medical devices and electrophy equipment. It creates electrophysiological mapping systems for the treatment of cardiac arrhythmias, such as atrial fibrillation, and ventricular tachycardia. The company was founded by Randell L. Werneth and Christoph Scharf in 2011 and is headquartered in Carlsbad, CA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the third quarter and year-to-date of 2024.

Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results

CARLSBAD, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the second quarter and year-to-date of 2024.

Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial Results

CARLSBAD, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the first quarter of 2024.

Acutus Medical Reports First Quarter 2024 Financial Results

Acutus Medical (NASDAQ: AFIB ) stock is falling hard on Monday as investors prepare for the arrhythmias tool development company's delisting later this week. AFIB stock is being delisted due to its inability to reach the minimum bid price of $1 per share on the Nasdaq Exchange.

Why Is Acutus Medical (AFIB) Stock Down 41% Today?

CARLSBAD, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the fourth quarter and full year ended December 31,2023.

Acutus Medical Reports Fourth Quarter and Full Year 2023 Financial Results

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Eagle Pharmaceuticals

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That Could Blast Off This Quarter - Acutus Medical (NASDAQ:AFIB), Becton Dickinson (NYSE:BDX)

CARLSBAD, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), today announced that, following the Company's announcement of its strategic realignment of resources and corporate restructuring and release of its third quarter results on November 8, 2023, the Company will no longer hold its third quarter results conference call and webcast which was previously scheduled for Monday, November 13, 2023.

Acutus Medical to Cancel Third Quarter 2023 Conference Call

CARLSBAD, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the third quarter of 2023.

Acutus Medical Reports Third Quarter 2023 Financial Results

CARLSBAD, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), today announced a realignment of resources and corporate restructuring.

Acutus Medical Announces Strategic Realignment of Resources and Corporate Restructuring

CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on Monday, November 13, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Acutus Medical to Announce Third Quarter 2023 Financial Results

CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on November 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company's 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 5 individuals hired by Acutus in October 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acutus Medical, Inc. (NASDAQ:AFIB ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 AM ET Company Participants Caroline Corner - IR David Roman - CEO Takeo Mukai - CFO Conference Call Participants Marie Thibault - BTIG John Young - Canaccord Genuity Margaret Kaczor - William Blair Operator Good day, and thank you for standing by, and welcome to the Acutus Medical Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

Acutus Medical, Inc. (AFIB) Q2 2023 Earnings Call Transcript

Acutus Medical, Inc. (AFIB) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to earnings of $0.16 per share a year ago.

Acutus Medical, Inc. (AFIB) Reports Q2 Loss, Tops Revenue Estimates

CARLSBAD, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2023.

Acutus Medical Reports Second Quarter 2023 Financial Results

CARLSBAD, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will present at the 43rd Annual Canaccord Growth Conference on Thursday, August 10, 2023 at 9:30 a.m. Eastern Time at the InterContinental Boston Hotel in Boston, MA.

Acutus Medical to Present at the 43rd Annual Canaccord Growth Conference

CARLSBAD, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its second quarter 2023 financial results on Monday, August 7, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Acutus Medical to Announce Second Quarter 2023 Financial Results

CARLSBAD, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, is pleased to announce its participation in the upcoming Heart Rhythm Society (HRS) Annual Scientific Sessions in New Orleans, LA from May 19-21, 2023.

Acutus Medical to Showcase Innovative Cardiac Mapping and Ablation Technologies at HRS 2023

Acutus Medical, Inc. (NASDAQ:AFIB ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Caroline Corner - Investor Relations David Roman - President & Chief Executive Officer Takeo Mukai - Vice President of Finance & Accounting, Interim Chief Financial Officer Conference Call Participants John Young - BTIG Marie Thibault - BTIG Operator Good afternoon and thank you for standing by. Welcome to the Acutus Medical First Quarter 2023 Conference Call.

Acutus Medical, Inc. (AFIB) Q1 2023 Earnings Call Transcript

CARLSBAD, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2023.

Acutus Medical Reports First Quarter 2023 Financial Results

CARLSBAD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its first quarter 2023 financial results on Thursday, May 11, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Acutus Medical to Announce First Quarter 2023 Financial Results

CARLSBAD, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the first quarter 2023 in addition to the release of the RECOVER AF study data (published online in EP Europace)1 .

Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results

Start Time: 16:30 January 1, 0000 5:14 PM ET Acutus Medical, Inc. (NASDAQ:AFIB ) Q4 2022 Earnings Conference Call March 16, 2023, 16:30 PM ET Company Participants David Roman - President and CEO Takeo Mukai - VP, Finance & Accounting, Interim CFO Caroline Corner - IR Conference Call Participants Marie Thibault - BTIG Margaret Kaczor - William Blair William Plovanic - Canaccord Genuity Operator Thank you for standing by. Welcome to Acutus Medical's Fourth Quarter and Full Year 2022 Earnings Call.

Acutus Medical, Inc. (AFIB) Q4 2022 Earnings Call Transcript

Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of 158.57% and 3.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Acutus Medical, Inc. (AFIB) Q4 Earnings and Revenues Surpass Estimates

CARLSBAD, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the fourth quarter and full year ended December 31, 2022. Financial statements and other information presented for 2022 is unaudited.

Acutus Medical Reports Fourth Quarter and Full Year 2022 Financial Results

CARLSBAD, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

News for Acutus Medical Stock (AFIB)